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Background. Glycosylation is the most frequent posttranslational modification of proteins and lipids influencing inter- and
intracellular communication and cell adhesion. Altered glycosylation patterns are characteristically observed in tumour cells.
Normal and altered carbohydrate chains are transferred to their acceptor structures via glycosyltransferases. Here, we present the
correlation between the presence of three different glycosyltransferases and tumour characteristics. Methods. 235 breast cancer
tissue samples were stained immunohistochemically for the glycosyltransferases N-acetylgalactosaminyltransferase 6 (GALNT6),
𝛽-1,6-N-acetylglucosaminyltransferase 2 (GCNT2), and ST6 (𝛼-N-acetyl-neuraminyl-2,3-𝛽-galactosyl-1,3)-N-acetylgalactosamine
𝛼-2,6-sialyltransferase 1 (ST6GALNac1). Staining was evaluated by light microscopy and was correlated to different tumour
characteristics by statistical analysis. Results. We found a statistically significant correlation for the presence of glycosyltransferases
and tumour size and grading. Specifically smaller tumours with low grading revealed the highest incidences of glycosyltransferases.
Additionally, Her4-expression but not pHer4-expression is correlated with the presence of glycosyltransferases. All other investi-
gated parameters could not uncover any statistically significant reciprocity. Conclusion. Here we show, that glycosyltransferases
can identify small tumours with well-differentiated cells; hence, glycosylation patterns could be used as a marker for early
tumourigenesis. This assumption is supported by the fact that Her4 is also correlated to glycosylation, whereas the activated form
of Her4 does not show such a connection with glycosylation.
1. Introduction
Glycosylation is the most common posttranslational modi-
fication of proteins and lipids, creating structural diversity
[1]. The addition of carbohydrate chains influences diverse
mechanisms such as cell-cell adhesion [2, 3], communication
of cells with their environment [4], or antigen recognition
by the immune system [5]. There are two major forms of
glycosylation: first, the so-called N-glycosylation. During
this process, oligosaccharide precursor chains are covalently
linked to Asparagine-residues of proteins. The second form
is called O-glycosylation. Here, in a first step, GalNAc
residues are attached to Serine- orThreonine-residues under
the control of ppGalNac-transferases [6–8]. These carbohy-
drate residues are later modified in a tissue-specific manner
[9, 10].
Cancer cells and tissues are often characterized by an
altered glycosylation pattern [11, 12]. As early as 1985, it
was shown that cancer tissues stain positive with antibodies
against abnormal carbohydrate chains [13]. Many of these
tumour associated carbohydrate antigens (TACAs) are well
known and described, for example, T-, Tn-, sTn-, and the
Lewis-antigens [14, 15], and have been studied extensively
in cell culture models [16, 17]. TACAs seem to regulate
cellular functions such as signal transduction, antigenicity,
interaction with immune effector cells, and cell-cell adhesion
[18–22]. Taken together, altered glycosylation seems to con-
tribute to tumourigenesis and tumour progression [23] and
hence might offer new targets for diagnosis, prognosis, and
therapeutic strategies [24–26].
In breast cancer, altered glycosylation has been linked to
a worse prognosis and a shortened overall survival before
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[27]. The most frequent alterations of glycosylation in breast
cancer are shortenedO-glycans [28] and increased sialylation
[29]. Moreover, altered glycosylation effects the morphologi-
cal transformation of tumour cells which can ultimately lead
to metastasis formation [6].
The main reason for the occurrence of altered glycosyla-
tion is a change in the expression of glycosyltransferases—the
responsible enzymes for glycosylation [30, 31].These enzymes
are located in the membranes of the endoplasmic reticulum
and the Golgi apparatus and transfer carbohydrate chains to
acceptormolecules.They are categorized in different subfam-
ilies with regard to the respective transferred carbohydrate.
Although the families share almost no sequence homologies
and do not have comparable exon-intron-structures, protein
domain structures are rather similar: they mostly have an
N-terminal cytoplasmatic tail, a signal anchor domain of
16–20 amino acids, an extended stem region, and a cat-
alytic C-terminal domain [32, 33]. Expression profiling of
glycosyltransferases has been studied extensively [34–38] and
it was reported that oncogenic transformation is regulated
at the transcriptional level [39]. Therefore, the expression
of glycosyltransferases is an important marker for tumour
prognosis and therapeutic outcome [40, 41].
In the present study, we sought to determine correlations
between the incidence of glycosyltransferases and other
tumour characteristics, such as histology, grading, tumour
size, expression of Her2 and Her4, or hormone receptor
status. For that purpose, three different glycosyltransferases,
namely, N-acetylgalactosaminyltransferase 6 (GALNT6),
𝛽-1,6-N-acetylglucosaminyltransferase 2 (GCNT2), and
ST6(𝛼-N-acetyl-neuraminyl-2,3-𝛽-galactosyl-1,3)-N-acetyl-
galactosamine 𝛼-2,6-sialyltransferase 1 (ST6GALNac1), were
immunohistochemically investigated in paraffin-embedded
tumour tissue sections. GALNT6 is involved in the first
steps of O-glycosylation [42]. It is known that breast
cancer expresses GALNT6 mRNA and this phenomenon is
mainly associated with smaller tumours (T1) [43]. GCNT2
is related to metastasis formation and influences cell
proliferation, migration, and invasion of endothelial cells
[44]. ST6GALNac1 synthesizes the sTn-antigen, which is
known to be overexpressed in epithelial cancers like breast
cancer. Moreover, the expression of ST6GALNac1 results in
increased cell migration and reduced cell adhesion [16].
It could be shown that GALNT6 especially is correlated
to a small tumour size and low grading, meaning that
small, still good differentiated tumours are glycosylated, and
thus glycosylation is a marker for a good prognosis for
therapy and outcome. Furthermore a correlation of all three
glycosyltransferases with Her4, but not with the activated
form of Her4, pHer4, could be seen. Her4 is also known to
be mostly expressed in tumour tissues which are still more
differentiated [45], supporting our hypothesis.
2. Materials and Methods
2.1. Tumour Tissue Samples. Tumour tissue samples of 235
breast cancer patients undergoing breast cancer surgery
between July 1998 and May 2000 were collected (ethical
vote 048-08 and 148-12, Ludwig-Maximilians University of
Munich, compliant to the Declaration of Helsinki), subse-
quently embedded in paraffin, and archived. Patient samples
in this study were not preselected for certain criteria and
therefore show different tumour characteristics with respect
to age at time of surgery, histology, grading, tumour size,
nodal state, formation of remote metastasis, and hormone
receptor state.
Tissue samples can be assigned to characteristics shown
in Figure 1.
2.2. Immunohistochemistry. The paraffin-embedded samples
were cut into 2-3 𝜇m thick sections with a sliding microtome,
subsequently placed on specially covered microscope slides
(SuperFrost Plus, Menzel GmbH, Braunschweig), and air-
dried over night at 56–58∘C. For immunohistochemical
staining, samples were deparaffinized with xylol (Merck,
Darmstadt, Germany) for 20min and successively washed
with different dilutions of ethanol (100%, 90%, and 75%).
To prevent unspecific staining of tissue samples, endogenous
peroxidase activity was reduced by incubation of the sam-




(VWR International, Radnor, USA) for
20min. Afterwards samples underwent further washes in
ethanol and water. Next, antigen retrieval was carried out
in boiling Na-citrate buffer (pH 6.00) for 5min. (Merck,
Darmstadt, Germany). After cooling down, tissue samples
were washed again in water and PBS (Biochrom, Berlin,
Germany).
The prepared slides were first blocked in 10% normal goat
serum for 20min (Vector Laboratories, Burlingame, USA)
to prevent unspecific binding of the primary antibody. After
removing the blocking solution, primary antibodies were
added in optimized concentrations (see Table 1).
Primary antibodies were incubated for 18 h at 4∘C. Slides
were then washed twice with PBS and subsequently incu-
bated with biotinylated secondary antibodies for 30min. at
room temperature. After removing the secondary antibody,
slides were treated with ABC-reagent (Vector Laboratories,
Burlingame, USA) according to the manufacturers’ instruc-
tions for 30min. Next, DAB-reagent (Dako, Carpinteria,




was added to the slides for 1min. for
ideal staining. Enzyme reaction was stopped by washing the
slides in water. Nuclei were counterstained with Hemalaun
(AppliChem, Darmstadt, Germany) for 5min. Last, samples
were dehydrated with ethanol and xylol and embedded in
Eukitt (Medite, Burgdorf, Germany). The stained samples
were then analysed and archived for further evaluations.
Before starting the staining procedure on tumour tissue
samples positive and isotype control have to be carried
out (Figure 2). For positive control a sample from a tissue
certainly expressing the antigen of interest is stained to
test antibody function and to determine an appropriate
dilution of the antibody for staining (Table 1). The isotype
control reveals background staining due to primary antibody.
Therefore the same tissue used for positive control (GALNT6:
Placenta, GCNT2: Colon, ST6GALNac1: Uterus) is stained,
but primary antibody is replaced by a control serum.

































































































































Figure 1: Characteristics of tumour samples used for staining of glycosyltransferases.
2.3. Microscopy and Evaluation of Staining. Samples were
analysed and evaluated with a Leitz Diaplan light microscope
(Ernst Leitz GmbH,Wetzlar, Germany). Four objectives with
different magnifications (6,3x, 10x, 25x, and 40x) were used
(Figure 3; Figure 2: positive and isotype controls).
Stainings were evaluated following the immune-reactive-
score (IRS) described by Remmele and Stegner in 1987 [46].
The IRS is obtained by multiplication of staining intensity
by the number of stained cells. Staining intensity can be
classified into groups from 0 to 3, with 0 being “no staining

















Figure 2: Positive control (a) and isotype control (b). For positive control tissues certainly expressing the questionable antigens were stained.
Placental tissue was used for GALNT6 staining, Colon tissue was used for GCNT2 and Uterus was chosen for ST6GALNac1 staining.
Furthermore appropriate antibody concentrations were determined in the positive controls. For isotype control same tissues as for positive
control are used, but primary antibody is replaced by a control serum, thus excluding unspecific binding signals of the primary antibody.
Table 1: Antibodies used for immunohistochemical staining of breast cancer tissue samples.
Antigen Host Isotype Manufacturer Positive control tissue Dilution (in PBS)
GALNT6 Rabbit Polyclonal IgG GeneTex Placenta 1 : 1000
GCNT2 Rabbit Polyclonal IgG Novus Biologicals Colon 1 : 400
ST6GALNac1 Rabbit Polyclonal IgG Novus Biologicals Uterus 1 : 500
reaction” and 3 being “strong colour reaction”; numbers of
stained cells are classified in a similar manner from 0, “0%
stained cells,” to 4 “81–100% stained cells.”Thus, the IRS is in a
range from0 to 12.The IRS of different tumour characteristics
were compared (Figure 4).
2.4. Statistical Evaluation. Statistical analysis was done by
SPSS (SPSS Inc. Headquarters, Chicago, USA) version 20.0.
As patient samples are not normally distributed, nonpara-
metric Mann-Whitney 𝑈 test was applied comparing two
variables; for more variables Kruskal-Wallis test was applied.
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Figure 3: Staining of malignant breast tissue with antibodies against the three glycosyltransferases GALNT6 (a), GCNT2 (b), and
ST6GALNac1 (c). Pictures were taken with different objectives (6,3x, 10x, 25x, and 40x; from left to right column) resulting in different
magnifications of tissue structures.
A 𝑃 value of ≤0,05 was regarded as statistically significant
(Table 2). Correlations were calculated with the Spearman-
Rho test. Survival curves were drawn using Kaplan-Meier
analysis (Figure 5).
3. Results and Discussion
235 tumour tissue samples were stained for all three different
glycosyltransferases (GALNT6, GCNT2, and ST6GALNac1)
(Figures 3 and 2 for controls) and their IRS was determined
by light microscopic and statistical evaluation. The resulting
IRS was then compared to multiple different tumour charac-
teristics in order to detect potential correlations.
First of all, we could not detect any association between
the histological subtype and the presence of glycosyl-
transferases (Figure 4(a)). Lobular and ductal breast cancer
revealed similar IRS for all three examined glycosyltrans-
ferases with no statistical significant difference (𝑃 = 0,203,
𝑃 = 0,984, and 𝑃 = 0,904 for GALNT6, GCNT2, and
ST6GALNac1, resp.; Table 2). Similarly, we could not detect
any significant differences of glycosyltransferase expression
in comparison to the nodal status or metastatic setting
(Figure 4(a), Table 2). When correlating the tumour grading
to the presence of glycosyltransferases, GALNT6 was sig-
nificantly higher expressed in low grade tumours (grades
1 and 2) compared to high grade tumours (grade 3)
(Figure 4(a), Table 2). GCNT2 and ST6GALNac1 were seem-
ingly higher expressed in the same group, however, at a
level of borderline significance (𝑃 = 0,104 for GCNT2 and
𝑃 = 0,094 for ST6GALNac1). With reference to tumour
size, we were able to find a similar tendency (Figure 4(a),
Table 2). Here, IR-scores for all three enzymeswere higher for
smaller tumours (Cis and T1) compared to bigger tumours
(𝑇 ≥ 2), with a significant difference for GALNT6 (𝑃
= 0,012) and borderline significant difference for the other
two investigated glycosyltransferases (GCNT2: 𝑃 = 0,066,
ST6GALNac1: 𝑃 = 0,059) (Figure 4(a), Table 2). However
there seem to be coherences between tumour grading and
tumour size and glycosyltransferases. The results suggest
that tumours of low grading (grades 1 and 2) are seemingly
more dependent on glycosyltransferases than tumours of
high grading (grade 3). The latter group contains tumours
that are much more dedifferentiated and underwent major
changes in their cellular structure making them possibly






















































































































































































































































Figure 4: (a) Comparison of IRS-values of glycosyltransferases with histological subtype, nodal status, grading, tumour size, and metastasis.
(b) Comparison of IRS-values of glycosyltransferases with Her2, ER, and PR status and Her4 and pHer4.
more independent from glycosyltransferase enzymes. With
reference to tumour size, we were able to find a similar
tendency (Figure 4(a), Table 2). Furthermore IR-scores for all
three enzymes were higher for smaller tumours (Cis and T1)
compared to bigger tumours (𝑇 ≥ 2) leading to the thought
that glycosyltransferases are important in early phases of
breast tumorigenesis. GALNT6 especially seems to play a role
in early tumour formation, a finding that is in consistency
with the results of Berois et al. [43]. GALNT6 seems to be
characteristic of small, low grade tumours while GCNT2 and
8 BioMed Research International
Table 2: Statistical analysis of the investigated features. Statistically
significant 𝑃 values are seen for Her4 (all glycosyltransferases)









ductal versus lobular 0,203 0,948 0,904
Nodal status,
negative versus positive 0,532 0,331 0,891
Metastatic status,
0 versus 1 0,957 0,383 0,497
Grading,
1 and 2 versus 3 0,029 0,104 0,094
Tumour size,
CIS and 1 versus 2, 3, and 4 0,012 0,066 0,059
Her4,
negative versus positive 0,003 0,005 0,001
pHer4,
negative versus positive 0,622 0,113 0,039
Her2 status,
negative versus positive 0,142 0,925 0,077
Estrogenreceptor status,




ST6GALNac1 are obviouslymarkers of a little more advanced
tumour stage, with higher IRS-values in metastatic patient
tissue samples and also with a little higher correlation toOAS,
which is again in line with former findings [44]. Another
correlation was seen between the glycosyltransferases and
Her4/pHer4 (Figure 4(b), Table 2), as we detected that the
nonphosphorylated form of Her4 seems to correlate strongly
with the presence of all three glycosyltransferases (𝑃 =
0,003, 𝑃 = 0,005, and 𝑃 = 0,001 for GALNT6, GCNT2,
and ST6GALNac1, resp.), while the phosphorylated form,
pHer4, did not. Only IR-scores of ST6GALNac1 correlated
at a statistically significant level with the presence of pHer4
(𝑃 = 0,039). Her4 is another member of the family of
epidermal growth factor receptors and is, hence, a receptor
tyrosine kinase. Epidermal growth factor binds to one of the
type I transmembrane receptors which leads to a homo- or
heterodimerization and subsequently activates the intrinsic
kinase domain by autophosphorylation. The phosphorylated
domain then serves as starting point for many intracellular
signalling cascades [47]. In our observations, we detected
that the “inactive,” nonphosphorylated form ofHer4 seems to
correlate strongly with the presence of all three glycosyltrans-
ferases, while the “activated,” phosphorylated form, pHer4,
did not correlate at such a strong level. Only IR-scores of
ST6GALNac1 correlated at a statistically significant level with
the presence of pHer4.
Her2 or the hormone receptors for Estrogen and Pro-
gesterone did not reveal any significant correlations to
the presence of glycosyltransferases (Figure 4(b), Table 2).
Only the presence of Her2 showed a borderline signifi-
cance with IR-scores for ST6GALNac1 (𝑃 = 0,077); however,
GALNT6 and GCNT2 did not appear to be correlated with
Her2.
Last, we tried to evaluate whether expression of glycosyl-
transferases correlated with the overall survival of patients
included into this study. The Kaplan-Meier curves indicate
that survival is not dependent on glycosylation (Figure 5),
since high or low IR-scores did not deviate significantly (𝑃
values: GALNT6: 0,802, GCNT2: 0,406, and ST6GALNac1:
0,422).
All these findings are showing and underline a strong
coherence between early tumorigenesis and the increased
presence of glycosyltransferases.
4. Conclusion
From the results presented and discussed in the present
study, we conclude that glycosylation of tumour cells does
not correlate with tumour histology, formation of metastasis,
nodal status, or hormone receptors. On the other hand,
glycosyltransferases seem to be abundantly expressed in small
and well-differentiated tumours. It is known that altered
glycosylation can protect malignant cells from recognition
by the immune system [48]. Specifically small and nascent
tumours are prone to escape immunosurveillance in order to
establish tumour growth and supportive cancer microenvi-
ronment. Hence, the overexpression of such enzymes might
indicate a useful early step in breast tumorigenesis.
Of the three investigated glycosyltransferases, GALNT6
seems to offer the best correlations with regard to tumour
size and grading. Since GALNT6 catalyses early steps in O-
glycosylation [43] and therefore plays a central role in the
process of glycosylation, it stands out as a potential marker.
A further interesting focus for future research could
be to clarify the interrelation between Her4/pHer4 and
glycosylation patterns. It is well known that Her4 is heav-
ily glycosylated [45] and could serve in combination with
GALNT6 to detect starting and endpoint of the glycosylation
cascade. Once Her4 becomes activated by phosphorylation,
intracellular signalling pathways are activated, leading to fur-
ther dedifferentiation of tumour cells. This might eventually
lead to a reduction of glycosylation. On the other hand, Her4
is regarded as amarker of favourable prognosis [45], since it is
inversely correlated with the histological grading of a tumour
[49] and is elevated in sera of early breast cancer patients
[50]. In this regard, our data confer the correlation of Her4
to the presence of glycosyltransferases, especially its presence
in small tumours and good differentiation.
The above-described hypothesis requires further insights
and research. Additionally, the role of ST6GALNac1 should
be investigated in more detail, since this glycosyltransferase
in particular seems to be correlated with pHer4 and Her2.
It is the task of future research to analyse a wider
array of glycosyltransferases for their role in tumour for-
mation and progression, depicting a more detailed scheme
of the roles of different glycosyltransferases in early and
later tumorigenesis. Additionally the role of glycosyltrans-
ferases should be investigated in other gynaecological


































Figure 5: Kaplan-Meier analysis of overall survival with respect to glycosyltransferase expression. 𝑃 values indicate that no differences in
overall survival were found in respect to glycosyltransferase expression.
tumour entities, like ovarian or endometrial adenocarcino-
mas to gain more detailed insight into the onset of cancer
formation.
The results of the presented experiments furthermore
give a hint towards the utility of the methodology and
the usefulness of glycosyltransferases in terms of tumour
characterization. The method is fast and cost-efficient and
glycosyltransferases play an important role in tumour devel-
opment and are independent of processes like epithelial
mesenchymal transformation (EMT), so that they could be
useful biomarkers in the analysis of tumour tissue samples.
This could in turn help to individualize tumour treatment,
reducing side effects of any applied therapy while simultane-
ously increasing the efficiency of a therapy.
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